Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

Acute Myelogenous Leukemia (AML) Clinical Trial

Official title:

Pilot Trial of Two Dose Levels of Thymoglobulin as Part of a Myeloablative-Conditioning for a Human Leukocyte Antigen (HLA) Identical Matched Related Donor (MRD) Stem Cell Transplant (SCT) With Cyclosporine (CSa) as Post-transplant Graft vs. Host Disease (GvHD) Prophylaxis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00088543
• Other study ID #: SMC-101-1026
• Status: Completed
• Phase: N/A
• First received: July 29, 2004
• Last updated: March 16, 2015
• Start date: March 2004
• Est. completion date: April 2006

Study information

• Verified date: March 2015
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study involves the use of a drug called Thymoglobulin, which is approved in the USA to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection. Thymoglobulin is not approved for the treatment or prophylaxis of graft versus host disease in bone marrow transplantation. This study is to evaluate two (2) doses of Thymoglobulin and its safety and effectiveness when used with a "myeloablative" conditioning regimen prior to receiving a stem cell transplant (also called bone marrow transplantation) from a matched, related donor.

A myeloablative regimen is typically composed of chemotherapy and radiation and destroys the subject's existing bone marrow.

Subjects meeting all inclusion and exclusion criteria and who have a relative with matching (genetically similar) stem cells who are also willing to donate them (i.e. matched-related-donor) are eligible to participate in this study. Following myeloablative therapy, the donor's cells are then transplanted (i.e. infused) into the subject's blood stream.

One of the most common complications of this type of transplant is graft-versus-host disease (GvHD). This is a condition where the transplanted donor cells attack the transplant recipient's body. Treatments, such as cyclosporine, are used to minimize the risk of GvHD following stem cell transplantation.

To enter this study, subjects must be having a matched-related donor stem cell transplant. If a subject qualifies for entry into this study, he/she will be assigned to receive Thymoglobulin at a dose of 4.5 mg/kg or 8.5 mg/kg. The treatment assignment is random and is not chosen by the subject or their physician.

Subjects are admitted to the hospital for the transplant procedure and are treated with Thymoglobulin over 3-5 days just prior to receiving the donor stem cells. The subject will also receive standard GvHD prophylaxis with cyclosporine. Methotrexate, which is commonly used by transplant centers to minimize the risk of GvHD, will not be used in this study.

Subjects will be monitored during treatment with Thymoglobulin and during the transplant hospitalization. Additional subject monitoring occurs at month 1, 100 days and 6 months following the transplant.

Approximately 60 study subjects from approximately 14 transplant centers in the United States and Canada will be enrolled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: April 2006
• Est. primary completion date: April 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Subject has an HLA-A, -B and -DRB1 identical related donor and must be fully matched at Class II. A high resolution molecular HLA typing (at least 4 digits) is mandatory for HLA Class II and optional for HLA Class I

• Subject has confirmed diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) with acute myeloid leukemia (including secondary leukemia) in first complete remission (CR2) or acute lymphoid in CR1 or CR2.

• Subject is >= 18 and <= 55 years of age.

• Subject is receiving a myeloablative-conditioning regimen

• Men and women of childbearing age potential agree to practice an acceptable and reliable form of contraception during the study. Women must not be lactating or pregnant, and must have a negative serum pregnancy test.

• Subject has been fully informed and has signed an IRB-approved informed consent form.

• Subject is willing and able to follow study procedures for the 6 months post-transplant.

• The subject must be serologically negative for human immunodeficiency virus (HIV).

• Subject agrees to be followed for possible long-term safety outcomes for up to 12 months post-transplant.

• Subject has an ECOG performance score of 0-2.

• Subject has a creatinine of < 2.0mg/dL or creatinine clearance of > 50mL/min.

• Subject has an ejection fraction of >= 40%

• Subject has a serum bilirubin of < 2mg/dL.

Exclusion Criteria:

• Subject is receiving fludarabine, a non-myeloablative regimen, or other purine analogues as part of the conditioning regimen.

• Subject is receiving an ex vivo engineered or processed graft (CD34+ enrichment, T-cell depletion, etc.)

• Subject has documented uncontrolled central nervous system (CNS) disease.

• Subject is expected to receive or has received methotrexate for GvHD prophylaxis.

• Subject has alanine aminotransferase (ALT)or aspartate aminotransferase (AST) level of > 3x the upper limit of normal range within 3 weeks prior to transplant.

• Subject has used any experimental agent within 30 days prior to the date of signing the informed consent.

• Subject is receiving or has received a bone marrow transplant from a donor who has positive serology for HIV, hepatitis B virus(HBV), hepatitis C virus (HCV) or syphilis.

• Subject has a known contraindication to administration of rabbit anti-thymocyte globulin.

• Subject is currently abusing drugs or alcohol or, in the opinion of the Investigator, is at high risk for poor compliance.

• Subject, who in the opinion of the Investigator, has significant medical or psychological problems that warrants exclusion. Examples of significant problems include, but are not limited to, morbid obesity or severe cardiac disease.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Acute Lymphocytic Leukemia (ALL)
• Acute Myelogenous Leukemia (AML)
• Graft vs Host Disease
• Graft vs. Host Disease (GvHD)
• Leukemia
• Leukemia, Lymphoid
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Biological:
• Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
total dose 4.5 mg/kg
• Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
total dose 8.5 mg/kg

Locations

Country	Name	City	State
Canada	Ottawa Hospital - General Campus	Ottawa	Ontario
Canada	Princess Margaret Hospital, University Health Network	Toronto	Ontario
United States	Emory University Hospital	Atlanta	Georgia
United States	University of Alabama-Birmingham Hospital	Birmingham	Alabama
United States	Dana Farber Cancer Institute Dana 1B11	Boston	Massachusetts
United States	Massachusetts General Hospital Cox Bldg Room 640	Boston	Massachusetts
United States	Beth Israel Deaconess Medical Center KS121	Brookline	Massachusetts
United States	Duke University Medical Center	Durham	North Carolina
United States	Shands at the University of Florida, Division of Hematology/Oncology	Gainesville	Florida
United States	Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey
United States	UCLA Medical Center	Los Angeles	California
United States	The Nebraska Medical Center	Omaha	Nebraska
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Washington University School of Medicine	St. Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Genzyme, a Sanofi Company

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Grade II to IV acute GvHD in the first 100 days after transplant.		100 days	Yes
Secondary	Incidence of treatment related adverse events and serious adverse events at 100 days and 6 months post transplant		100 days and 6 months	Yes
Secondary	Patient survival at 100 days and 6 months after transplant		100 days and 6 months	Yes
Secondary	transplant related mortality at 100 days or 6 months after transplant		100 days and 6 months	Yes
Secondary	severity and outcomes of acute GvHD		100 days & 6 mos	Yes
Secondary	any events of infection at 100 days and 6 months after transplant		100 days and 6 months	Yes
Secondary	incidence (or absence) of mucositis		continuous	Yes
Secondary	how many days in the first month after transplant certain types of narcotics are used to reduce pain		30days	Yes
Secondary	whether the subject's blood counts after transplant reach a stable level and how quickly		Continuous	Yes
Secondary	incidence of re-hospitalization in the first 6 months after transplant		6 months	Yes
Secondary	any recurrence of the subject's leukemic disease, and how long the subject was able to stay in remission		Continuous	Yes
Secondary	incidence and severity of chronic GvHD, and the extent, after 100 days and 6 months after transplant		100 days and 6 months	Yes
Secondary	Disease free survival		100 days and 6 months	Yes

External Links

•   US FDA Approved Full Prescribing Information for Thymoglobulin®